|Day Low/High||101.61 / 104.55|
|52 Wk Low/High||65.57 / 125.86|
Partners Direct Relief and Habitat for Humanity International will focus on rebuilding primary healthcare system and ensuring access to affordable, disaster-resilient housing, respectively
- More than 30 abstracts accepted across hematologic malignancies, solid tumors and other oncology-related diseases
As cannabis becomes more and more legal, investors have started to wonder what that means for them.
KLA-Tencor, Microsoft and Intel all report earnings after the close Thursday.
- In clinical studies, more than half of patients receiving risankizumab achieved complete skin clearance (PASI 100) at one year (52 weeks) (1)
Jim Cramer and our other experts discus China and tariffs, the 10 year nearing 3%, technical analysis, and biotech stocks.
I think M&A activity will pick up markedly going forward across the industry.
Jim Cramer highlights Spotify, Alkermes, Sorrento Therapeutics, Thermo Fisher Scientific, Kohlberg Kravis Roberts, and more.
Washington receded and earnings came to the fore, but we're still seeing insane values and some surprises, says Jim Cramer.
The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.
The drug company generates about 60% of revenue outside the U.S.
The company will not need to worry about Biogen and Samsung Bioepis launching a biosimilar to challenge the reign of its blockbuster arthritis drug until 2023 after the three companies settled patent actions.
- Agreements Provide Non-Exclusive License to Samsung Bioepis for HUMIRA-Related Intellectual Property in the U.S. Effective June 30, 2023, and in Other Markets on Different Dates
These names are displaying signs of either bullish or bearish reversal patterns over the past week.
The legal cannabis industry could be worth $24 billion by 2025. Are you willing to pass that up?
Here comes the growth. These four strong buy biotech stocks are potentially on the cusp of very big growth.
Jim Cramer calls it a tsunami of selling. Not one sector of the stock market got a break in Thursday's tariff-inspired decline.
Here's what you need to know now for Thursday, March 22.
No sector offered respite from Thursday's tariff-inspired selloff.
The biopharma company's shares took a dive on Thursday, March 22, after it said it will not seek accelerated approval for Rova-T in third-line relapsed/refractory small-cell lung cancer.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.